| Original language | English (US) |
|---|---|
| Pages (from-to) | 226-228 |
| Number of pages | 3 |
| Journal | Ophthalmology Retina |
| Volume | 4 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2020 |
ASJC Scopus subject areas
- Ophthalmology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Anti–Vascular Endothelial Growth Factor Therapy for Choroidal Rupture-Associated Choroidal Neovascularization. / Russell, Jonathan F.; Albini, Thomas A.; Berrocal, Audina M.; Dubovy, Sander R.; Rosenfeld, Philip J.; Smiddy, William E.; Sridhar, Jayanth; Townsend, Justin H.; Flynn, Harry W.
In: Ophthalmology Retina, Vol. 4, No. 2, 02.2020, p. 226-228.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Anti–Vascular Endothelial Growth Factor Therapy for Choroidal Rupture-Associated Choroidal Neovascularization
AU - Russell, Jonathan F.
AU - Albini, Thomas A.
AU - Berrocal, Audina M.
AU - Dubovy, Sander R.
AU - Rosenfeld, Philip J.
AU - Smiddy, William E.
AU - Sridhar, Jayanth
AU - Townsend, Justin H.
AU - Flynn, Harry W.
N1 - Funding Information: Supported in part by Research to Prevent Blindness, Inc, New York, New York; and the National Eye Institute, National Institutes of Health, Bethesda, Maryland (center core grant no.: P30EY014801). The funding organizations had no role in the design or conduct of this research. Financial Disclosure(s): The author(s) have made the following disclosure(s): T.A.A.: Consultant Allegro Ophthalmics, Beaver Visitec, Clearside Biomedical, Eyepoint Pharmaceuticals, Genentech, Jannsen Biotech, Notal Vision, Novartis, Santen, Valeant. P.J.R.: Consultant ? Apellis Pharmaceuticals, Boehringer-Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotech, Healios K.K., Hemera Biosciences, F. Hoffmann-La Roche Ltd, Isarna Pharmaceuticals, Lin Bioscience, NGM Biopharmaceuticals, Ocunexus Therapeutics, Ocudyne, Unity Biotechnology; Financial support ? Carl Zeiss Meditec, Inc, Genentech, Boehringer-Ingelheim; Equity interest ? Apellis, Verana Health, Ocudyne. Obtained funding: None
PY - 2020/2
Y1 - 2020/2
UR - http://www.scopus.com/inward/record.url?scp=85078657403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078657403&partnerID=8YFLogxK
U2 - 10.1016/j.oret.2019.09.008
DO - 10.1016/j.oret.2019.09.008
M3 - Article
AN - SCOPUS:85078657403
VL - 4
SP - 226
EP - 228
JO - Ophthalmology Retina
JF - Ophthalmology Retina
SN - 2468-7219
IS - 2
ER -